[Systemic autoimmune diseases].
Since Hench successfully treated a patient with rheumatoid arthritis (RA) with glucocorticoid (GC) in 1948, the clinical usefulness of GC in the management of systemic autoimmune diseases has been established. However, serious adverse reactions of GC are the severe clinical problems. In addition, some of clinical evidences of GC therapy for these diseases are still controversial due to the difficulties for conducting clinical trials. In this review, we summarize the significance of GC therapy in autoimmune diseases such as RA and systemic lupus erythematosus, based upon the clinical reports for these diseases.
Kawai
Shinichi
S
Division of Rheumatology, Department of Internal Medicine (Omori), Toho University School of Medicine.
Takagi
Kenji
K
Kusunoki
Yoshie
Y
Nishio
Shinichiro
S
Matsumoto
Nahoko
N
D000293:Adolescent; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male
D005938:Glucocorticoids